Morgan Stanley is out with its report today on Medco Health Solutions MHS, maintaining Overweight.
In a note to clients, Morgan Stanley writes, "Framing a bear case scenario, if MHS were to retain only 92% of its ~$17 billion in revenues up for renewal (mirroring CVS' renewal rates in the 2009/2010 season) as compared to
historical 99% retention rate, we quantify an EPS impact of ~ $0.10 to $0.15 to our 2012e EPS of $5.12. Under that scenario, ESRX may stand to gain share."
At the time of posting, shares of MHS were trading pre-market at $57, up 1.37% from Wednesday's close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.